الفهرس 
Cirrhotic CardiomyopathyOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Cirrhotic cardiomyopathy is a recently recognized condition in cirrhosis consisting of systolic incompetence under condition of stress, diastolic dysfunction related to altered diastolic relaxation and electrophysiological abnormalities in the absence of any known cardiac disease. It can be diagnosed by using a combination of electrocardiograph, 2-dimensional echocardiography, and various serum markers such as brain natriuretic factor.
Our study was aiming to evaluate the brain natriuretic peptide as a marker for the diagnosis of cirrhotic cardiomyopathy in hepatocellular carcinoma patients before and after radiofrequency ablation.
This study was conducted on 30 patients with chronic liver disease 20 patients with HCC candidates for RFA as a patient group and group B 10 patients with CLD (child A) as a control group.
Evaluation of presence of cirrhotic cardiomyopathy was done by measuring serum BNP level before and after radiofrequency ablation by one week and performing echocardiography.
In this study there was no significant statistical difference between both groups as regards BNP or EF% before RFA.
Also no significant difference between liver function tests with BNP or EF% before RFA.
There was no significant correlation between BNP and parameters of cardiac dysfunction in echocardiography (EF% , E/A ratio , deceleration time) in patient group before RFA.
After RFA by one week there was no significant difference in BNP , EF% , E/A ratio and deceleration time before and after RFA.
In this study after RFA , BNP did not correlate significantly with any parameter of echocardiography of CCM.
We conclude that BNP and echocardiography might not be conclusive or diagnostic for unmasking any mild cardiac dysfunction in (child A) cirrhotic patients after RFA.